• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
GAN Changjiao,CHEN Li,YUAN Yanfang,FANG Jun.Analysis of the implementation status and countermeasures of drug marketing authorization holder system in china[J].Journal Of Pharmaceutical Research,2024,43(5):449-454[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3010times   Download 2735次 QR Code for this article
Scan with your phone!
我国药品上市许可持有人制度的实施现状及对策分析
干长姣,程立,元延芳,房军
Font:Larger+|Default|Smaller-
(国家药品监督管理局高级研修学院,北京 100073)
摘要:
药品上市许可持有人(Marketing Authorization Holder,MAH)制度是贯穿2019年《药品管理法》的核心制度和基本制度。本文汇总整理了我国MAH制度实施以来的制度文件,结合我国药品产业及监管实际情况并借鉴国际经验,提出强化持有人履责能力、探索建立统一且独立的药品跨省监管机制、探索建立独立于生产、质量管理体系之外的第三方监控体系和完善细化MAH制度的法规政策等建议,以期进一步发挥MAH制度在优化资源配置、落实持有人主体责任等方面的作用。
关键词:  药品上市许可持有人制度  委托生产  药品监管
DOI:10.13506/j.cnki.jpr.2024.05.007
基金项目:国家药品监督管理局高级研修学院院内基金(No.NMPAIED102022008)
Publication Date:May 25, 2024
Analysis of the implementation status and countermeasures of drug marketing authorization holder system in china
GAN Changjiao,CHEN Li,YUAN Yanfang,FANG Jun
(National Medical Products Administration Institute of Executive Development,Beijing 100073,China)
Abstract:
The Marketing Authorization Holder (MAH) system is the core and basic system throughout the Drug Administration Law of the People's Republic of China. To further leverage the role of the MAH system in optimizing resource allocation and implementing the primary responsibility of holders, institutional documents since the implementation of the MAH system in China has been summarized and organized. Based on the actual situation of China's pharmaceutical industry and its regulation, as well as drawing on international experience, targeted improvement suggestions are proposed. Such as strengthening the holders to perform their duties responsibly, exploring the establishment of a unified and independent cross-provincial regulatory mechanism and a third regulator, and improving the laws and regulations of the MAH system.
Key words:  Marketing Authorization Holder (MAH) system  Commissioned production  Drug regulation  Advice
Today's Visits:510    Total Visits:2383241
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.